Literature DB >> 21765024

Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS.

Qian Zhang1, Hongyi Wang, Kanchan Kantekure, Jennifer C Paterson, Xiaobin Liu, Andras Schaffer, Chrystal Paulos, Michael C Milone, Niels Odum, Suzanne Turner, Teresa Marafioti, Mariusz A Wasik.   

Abstract

Here we report that T-cell lymphoma cells carrying the NPM-ALK fusion protein (ALK(+) TCL) frequently express the cell-stimulatory receptor ICOS. ICOS expression in ALK(+) TCL is moderate and strictly dependent on the expression and enzymatic activity of NPM-ALK. NPM-ALK induces ICOS expression via STAT3, which triggers the transcriptional activity of the ICOS gene promoter. In addition, STAT3 suppresses the expression of miR-219 that, in turn, selectively inhibits ICOS expression. ALK(+) TCL cell lines display extensive DNA methylation of the CpG island located within intron 1, the putative enhancer region, of the ICOS gene, whereas cutaneous T-cell lymphoma cell lines, which strongly express ICOS, show no methylation of the island. Treatment of the ALK(+) TCL cell lines with DNA methyltransferase inhibitor reversed the CpG island methylation and augmented the expression of ICOS mRNA and protein. Stimulation of the ICOS receptor with anti-ICOS antibody or ICOS ligand-expressing B cells markedly enhanced proliferation of the ALK(+) TCL cells. These results demonstrate that NPM-ALK, acting through STAT3 as the gene transcriptional activator, induces the expression of ICOS, a cell growth promoting receptor. These data also show that the DNA methylation status of the intronic CpG island affects transcriptional activity of the ICOS gene and, consequently, modulates the concentration of the expressed ICOS protein.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21765024      PMCID: PMC3175783          DOI: 10.1182/blood-2011-01-332916

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

Review 1.  Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS).

Authors:  Tyler R Simpson; Sergio A Quezada; James P Allison
Journal:  Curr Opin Immunol       Date:  2010-01-29       Impact factor: 7.486

2.  The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation.

Authors:  Teresa Marafioti; Jennifer C Paterson; Erica Ballabio; Andreas Chott; Yasodha Natkunam; Manuel Rodriguez-Justo; Anne Plonquet; Socorro M Rodriguez-Pinilla; Wolfram Klapper; Martin-L Hansmann; Stefano A Pileri; Peter G Isaacson; Harald Stein; Miguel A Piris; David Y Mason; Philippe Gaulard
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

Review 3.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

4.  Activation of mTORC1 signaling pathway in AIDS-related lymphomas.

Authors:  Mouna El-Salem; Puthiyaveettil N Raghunath; Michal Marzec; Xiaobin Liu; Monika Kasprzycka; Erle Robertson; Mariusz A Wasik
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

5.  Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes.

Authors:  Monika Kasprzycka; Qian Zhang; Agnieszka Witkiewicz; Michal Marzec; Magdalena Potoczek; Xiaobin Liu; Hong Yi Wang; Michael Milone; Samik Basu; Joanne Mauger; John K Choi; J Todd Abrams; J Steven Hou; Alain H Rook; Eric Vonderheid; Anders Woetmann; Niels Odum; Mariusz A Wasik
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

Review 6.  The anaplastic lymphoma kinase in the pathogenesis of cancer.

Authors:  Roberto Chiarle; Claudia Voena; Chiara Ambrogio; Roberto Piva; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

Review 7.  Epigenetic opportunities and challenges in cancer.

Authors:  Jonathan D Best; Nessa Carey
Journal:  Drug Discov Today       Date:  2009-11-06       Impact factor: 7.851

8.  ICOS controls the pool size of effector-memory and regulatory T cells.

Authors:  Yvonne Burmeister; Timo Lischke; Anja C Dahler; Hans Werner Mages; Kong-Peng Lam; Anthony J Coyle; Richard A Kroczek; Andreas Hutloff
Journal:  J Immunol       Date:  2008-01-15       Impact factor: 5.422

9.  Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis.

Authors:  C Coquerelle; G Oldenhove; V Acolty; J Denoeud; G Vansanten; J-M Verdebout; A Mellor; J A Bluestone; M Moser
Journal:  Gut       Date:  2009-06-07       Impact factor: 23.059

10.  Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses.

Authors:  Li-Fan Lu; Mark P Boldin; Ashutosh Chaudhry; Ling-Li Lin; Konstantin D Taganov; Toshikatsu Hanada; Akihiko Yoshimura; David Baltimore; Alexander Y Rudensky
Journal:  Cell       Date:  2010-09-17       Impact factor: 41.582

View more
  16 in total

Review 1.  Dysregulation of microRNAs and their association in the pathogenesis of T-cell lymphoma/leukemias.

Authors:  Sho Ikeda; Hiroyuki Tagawa
Journal:  Int J Hematol       Date:  2014-02-25       Impact factor: 2.490

Review 2.  New molecular insights into peripheral T cell lymphomas.

Authors:  Stefano A Pileri; Pier Paolo Piccaluga
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

3.  Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability.

Authors:  Carlos Murga-Zamalloa; Delphine C M Rolland; Avery Polk; Ashley Wolfe; Hiran Dewar; Pinki Chowdhury; Ozlem Onder; Rajan Dewar; Noah A Brown; Nathanael G Bailey; Kedar Inamdar; Megan S Lim; Kojo S J Elenitoba-Johnson; Ryan A Wilcox
Journal:  Clin Cancer Res       Date:  2019-10-21       Impact factor: 12.531

4.  Genetics of anaplastic large cell lymphoma.

Authors:  Yu Zeng; Andrew L Feldman
Journal:  Leuk Lymphoma       Date:  2015-07-21

5.  Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner.

Authors:  Qian Zhang; Hong Yi Wang; Fang Wei; Xiaobin Liu; Jennifer C Paterson; Darshan Roy; Daniela Mihova; Anders Woetmann; Andrzej Ptasznik; Niels Odum; Stephen J Schuster; Teresa Marafioti; James L Riley; Mariusz A Wasik
Journal:  J Immunol       Date:  2014-02-12       Impact factor: 5.422

Review 6.  The role of B7 family molecules in hematologic malignancy.

Authors:  Paul Greaves; John G Gribben
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

7.  The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

Authors:  Raymond Lai; Robert J Ingham
Journal:  Ther Adv Hematol       Date:  2013-04

Review 8.  Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma.

Authors:  Fabrizio Tabbò; Maurilio Ponzoni; Raul Rabadan; Francesco Bertoni; Giorgio Inghirami
Journal:  Curr Opin Hematol       Date:  2013-07       Impact factor: 3.284

9.  S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma.

Authors:  Yong Liu; Jiehui Deng; Lin Wang; Heehyoung Lee; Brian Armstrong; Anna Scuto; Claudia Kowolik; Lawrence M Weiss; Stephen Forman; Hua Yu
Journal:  Blood       Date:  2012-06-28       Impact factor: 22.113

Review 10.  A three-signal model of T-cell lymphoma pathogenesis.

Authors:  Ryan A Wilcox
Journal:  Am J Hematol       Date:  2015-11-17       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.